Please Wait.....
Report
Middle East & Africa Cancer Immunotherapy Market - Industry Trends and Forecast to 2034
Market Report I 2023-12-01 I 292 Pages I Data Bridge Market Research
The Middle East and Africa cancer immunotherapy market is expected to reach USD 1,825.08 million by 2031 from USD 1,027.98 million in 2023, growing at a CAGR of 8.3% during the forecast period of 2024 to 2031.
Market Segmentation
Middle East and Africa Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (South Africa, Saudi Arabia, U.A.E., Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Middle East and Africa Cancer Immunotherapy Market Dynamics
Driver
- Rising prevalence of cancer incidences
Restraint
- Increasing occurrence of immune-related adverse events
Opportunity
- Growing trend towards combination therapies
Market Players
Some of the major market players operating in the Middle East and Africa cancer immunotherapy market are:
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Janssen Pharmaceutical
- AstraZeneca
- Gilead Sciences, Inc.
- Eli Lilly and Company
- Amgen Inc.
- Novartis AG
- GSK
- Pfizer Inc.
- Incyte
TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET 83
1.4 CURRENCY AND PRICING 85
1.5 LIMITATIONS 85
1.6 MARKETS COVERED 85
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 DBMR TRIPOD DATA VALIDATION MODEL 92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 96
2.8 MARKET END USER COVERAGE GRID 97
2.9 DBMR MARKET POSITION GRID 98
2.10 VENDOR SHARE ANALYSIS 99
2.11 SECONDARY SOURCES 100
2.12 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 103
4.1 PESTAL ANALYSIS 104
4.2 PORTERS 5 FORCES 105
5 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET: REGULATIONS 106
6 MARKET OVERVIEW 114
6.1 DRIVERS 116
6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 116
6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 116
6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 117
6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 117
6.2 RESTRAINTS 118
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 118
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 118
6.3 OPPORTUNITIES 119
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 119
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 119
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 120
6.4 CHALLENGES 121
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 121
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 121
7 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE 122
7.1 OVERVIEW 123
7.2 CHECKPOINT INHIBITORS 126
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 127
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 127
7.3 MONOCLONAL ANTIBODIES 128
7.3.1 NAKED MONOCLONAL ANTIBODIES 129
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 129
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 129
7.4 VACCINES 130
7.4.1 PROPHYLACTIC VACCINES 131
7.4.2 THERAPEUTIC VACCINES 131
7.5 CELL THERAPIES 131
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 132
7.5.2 T CELL THERAPY 132
7.6 IMMUNOMODULATORS 132
7.6.1 INTERFERONS 133
7.6.2 INTERLEUKINS 133
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 133
7.7 ONCOLYTIC VIRUS 134
8 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET , BY END USER 135
8.1 OVERVIEW 136
8.2 HOSPITALS 139
8.3 ONCOLOGY CLINICS 140
8.4 HOMECARE 140
8.5 OTHERS 141
9 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 142
9.1 OVERVIEW 143
9.2 DIRECT TENDERS 146
9.3 RETAIL SALES 147
9.4 PHARMACIES 147
9.4.1 HOSPITAL 148
9.4.2 RETAIL 148
9.4.3 ONLINE 148
10 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY FORM 149
10.1 OVERVIEW 150
10.2 INTRAVENOUS (IV) 153
10.3 INTRAMUSCULAR 154
10.4 ORAL 154
11 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155
11.1 OVERVIEW 156
11.2 LUNG CANCER 159
11.2.1 CHECKPOINT INHIBITORS 160
11.2.2 MONOCLONAL ANTIBODIES 160
11.2.3 CELL THERAPIES 160
11.2.4 IMMUNOMODULATORS 160
11.3 BREAST CANCER 161
11.3.1 CHECKPOINT INHIBITORS 161
11.3.2 MONOCLONAL ANTIBODIES 161
11.3.3 CELL THERAPIES 162
11.3.4 IMMUNOMODULATORS 162
11.4 MELANOMA 162
11.4.1 CHECKPOINT INHIBITORS 163
11.4.2 MONOCLONAL ANTIBODIES 163
11.4.3 CELL THERAPIES 163
11.4.4 IMMUNOMODULATORS 163
11.4.5 ONCOLYTIC VIRUS 163
11.5 MULTIPLE MYELOMA 164
11.5.1 CHECKPOINT INHIBITORS 164
11.5.2 MONOCLONAL ANTIBODIES 164
11.5.3 CELL THERAPIES 164
11.5.4 IMMUNOMODULATORS 165
11.6 PROSTATE CANCER 165
11.6.1 CHECKPOINT INHIBITORS 165
11.6.2 MONOCLONAL ANTIBODIES 166
11.6.3 CELL THERAPIES 166
11.6.4 IMMUNOMODULATORS 166
11.6.5 VACCINES 166
11.7 OVARIAN CANCER 166
11.7.1 CHECKPOINT INHIBITORS 167
11.7.2 MONOCLONAL ANTIBODIES 167
11.7.3 CELL THERAPIES 167
11.7.4 IMMUNOMODULATORS 167
11.8 CERVICAL CANCER 168
11.8.1 CHECKPOINT INHIBITORS 168
11.8.2 MONOCLONAL ANTIBODIES 168
11.8.3 VACCINES 169
11.8.4 CELL THERAPIES 169
11.8.5 IMMUNOMODULATORS 169
11.9 STOMACH CANCER 169
11.9.1 CHECKPOINT INHIBITORS 170
11.9.2 MONOCLONAL ANTIBODIES 170
11.9.3 CELL THERAPIES 170
11.9.4 IMMUNOMODULATORS 170
11.10 COLORECTAL CANCER 170
11.10.1 CHECKPOINT INHIBITORS 171
11.10.2 MONOCLONAL ANTIBODIES 171
11.10.3 CELL THERAPIES 171
11.10.4 IMMUNOMODULATORS 171
11.11 HEAD AND NECK CANCER 172
11.11.1 CHECKPOINT INHIBITORS 172
11.11.2 MONOCLONAL ANTIBODIES 172
11.11.3 CELL THERAPIES 172
11.11.4 IMMUNOMODULATORS 173
11.12 OTHERS 173
11.12.1 CHECKPOINT INHIBITORS 173
11.12.2 MONOCLONAL ANTIBODIES 173
11.12.3 VACCINES 174
11.12.4 CELL THERAPIES 174
11.12.5 IMMUNOMODULATORS 174
12 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, BY REGION 175
12.1 MIDDLE EAST AND AFRICA 177
12.1.1 SOUTH AFRICA 185
12.1.2 SAUDI ARABIA 193
12.1.3 U.A.E. 201
12.1.4 EGYPT 209
12.1.5 ISRAEL 217
12.1.6 OMAN 225
12.1.7 QATAR 233
12.1.8 BAHRAIN 241
12.1.9 REST OF MIDDLE EAST AND AFRICA 249
13 MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 250
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 250
14 SWOT ANALYSIS 251
15 COMPANY PROFILES 252
15.1 MERCK & CO., INC. 252
15.1.1 COMPANY SNAPSHOT 252
15.1.2 REVENUE ANALYSIS 252
15.1.3 COMPANY SHARE ANALYSIS 253
15.1.4 PRODUCT PORTFOLIO 253
15.1.5 RECENT DEVELOPMENTS 253
15.2 F. HOFFMANN-LA ROCHE LTD 254
15.2.1 COMPANY SNAPSHOT 254
15.2.2 REVENUE ANALYSIS 254
15.2.3 COMPANY SHARE ANALYSIS 255
15.2.4 PRODUCT PORTFOLIO 255
15.2.5 RECENT DEVELOPMENTS 255
15.3 BRISTOL-MYERS SQUIBB COMPANY 257
15.3.1 COMPANY SNAPSHOT 257
15.3.2 REVENUE ANALYSIS 257
15.3.3 COMPANY SHARE ANALYSIS 258
15.3.4 PRODUCT PORTFOLIO 258
15.3.5 RECENT DEVELOPMENTS 259
15.4 JANSSEN MIDDLE EAST AND AFRICA SERVICES, LLC 260
15.4.1 COMPANY SNAPSHOT 260
15.4.2 REVENUE ANALYSIS 260
15.4.3 COMPANY SHARE ANALYSIS 261
15.4.4 PRODUCT PORTFOLIO 261
15.4.5 RECENT DEVELOPMENTS 262
15.5 ASTRAZENECA 263
15.5.1 COMPANY SNAPSHOT 263
15.5.2 REVENUE ANALYSIS 263
15.5.3 COMPANY SHARE ANALYSIS 264
15.5.4 PRODUCT PORTFOLIO 264
15.5.5 RECENT DEVELOPMENTS 265
15.6 ABBVIE INC. 266
15.6.1 COMPANY SNAPSHOT 266
15.6.2 PIPELINE PORTFOLIO 266
15.6.3 RECENT DEVELOPMENTS 266
15.7 AMGEN INC. 267
15.7.1 COMPANY SNAPSHOT 267
15.7.2 REVENUE ANALYSIS 268
15.7.3 PIPELINE PORTFOLIO 268
15.7.4 PRODUCT PORTFOLIO 269
15.7.5 RECENT DEVELOPMENTS 269
15.8 ATARA BIOTHERAPEUTICS, INC. 270
15.8.1 COMPANY SNAPSHOT 270
15.8.2 PIPELINE PORTFOLIO 270
15.8.3 RECENT DEVELOPMENTS 270
15.9 BAYER AG 271
15.9.1 COMPANY SNAPSHOT 271
15.9.2 PIPELINE PORTFOLIO 271
15.9.3 RECENT DEVELOPMENTS 271
15.10 CELLDEX THERAPEUTICS. 273
15.10.1 COMPANY SNAPSHOT 273
15.10.2 PIPELINE PORTFOLIO 273
15.10.3 RECENT DEVELOPMENTS 273
15.11 CELLECTIS 274
15.11.1 COMPANY SNAPSHOT 274
15.11.2 PIPELINE PORTFOLIO 274
15.11.3 RECENT DEVELOPMENTS 274
15.12 GILEAD SCIENCES, INC. 275
15.12.1 COMPANY SNAPSHOT 275
15.12.2 REVENUE ANALYSIS 275
15.12.3 PRODUCT PORTFOLIO 276
15.12.4 RECENT DEVELOPMENTS 276
15.13 GSK PLC. 277
15.13.1 COMPANY SNAPSHOT 277
15.13.2 REVENUE ANALYSIS 277
15.13.3 PRODUCT PORTFOLIO 278
15.13.4 RECENT DEVELOPMENTS 278
15.14 INCYTE. 279
15.14.1 COMPANY SNAPSHOT 279
15.14.2 REVENUE ANALYSIS 279
15.14.3 PRODUCT PORTFOLIO 280
15.14.4 RECENT DEVELOPMENTS 280
15.15 LILLY. 281
15.15.1 COMPANY SNAPSHOT 281
15.15.2 REVENUE ANALYSIS 282
15.15.3 PRODUCT PORTFOLIO 282
15.15.4 RECENT DEVELOPMENTS 283
15.16 NOVARTIS AG 284
15.16.1 COMPANY SNAPSHOT 284
15.16.2 REVENUE ANALYSIS 284
15.16.3 PIPELINE PORTFOLIO 285
15.16.4 PRODUCT PORTFOLIO 285
15.16.5 RECENT DEVELOPMENTS 285
15.17 PFIZER INC. 286
15.17.1 COMPANY SNAPSHOT 286
15.17.2 REVENUE ANALYSIS 286
15.17.3 PRODUCT PORTFOLIO 287
15.17.4 RECENT DEVELOPMENTS 287
16 QUESTIONNAIRE 288
17 RELATED REPORTS 292
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security